Regeneron Pharmaceuticals (NASDAQ:REGN) Receives Overweight Rating from Wells Fargo & Company

Wells Fargo & Company reaffirmed their overweight rating on shares of Regeneron Pharmaceuticals (NASDAQ:REGN) in a report released on Monday, Benzinga reports. The firm currently has a $1,200.00 target price on the biopharmaceutical company’s stock.

Several other research firms have also recently commented on REGN. Barclays upped their target price on shares of Regeneron Pharmaceuticals from $1,200.00 to $1,220.00 and gave the stock an overweight rating in a research report on Friday, August 2nd. Royal Bank of Canada reaffirmed an outperform rating and set a $1,282.00 target price on shares of Regeneron Pharmaceuticals in a research note on Tuesday, September 17th. TD Cowen boosted their price target on Regeneron Pharmaceuticals from $1,030.00 to $1,200.00 and gave the stock a buy rating in a research report on Tuesday, July 23rd. Piper Sandler lifted their price objective on shares of Regeneron Pharmaceuticals from $1,166.00 to $1,242.00 and gave the company an overweight rating in a research note on Friday, August 23rd. Finally, JPMorgan Chase & Co. increased their target price on shares of Regeneron Pharmaceuticals from $1,150.00 to $1,200.00 and gave the company an overweight rating in a research report on Friday, August 2nd. One equities research analyst has rated the stock with a sell rating, four have given a hold rating, seventeen have given a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of Moderate Buy and an average target price of $1,118.62.

Regeneron Pharmaceuticals Stock Performance

Shares of REGN stock opened at $1,039.96 on Monday. The company has a quick ratio of 4.62, a current ratio of 5.44 and a debt-to-equity ratio of 0.10. The business has a 50 day moving average of $1,129.87 and a two-hundred day moving average of $1,033.99. The company has a market cap of $114.59 billion, a P/E ratio of 30.60, a PEG ratio of 3.72 and a beta of 0.12. Regeneron Pharmaceuticals has a 52 week low of $769.19 and a 52 week high of $1,211.20.

Regeneron Pharmaceuticals (NASDAQ:REGN) last issued its quarterly earnings data on Thursday, August 1st. The biopharmaceutical company reported $11.56 EPS for the quarter, topping analysts’ consensus estimates of $8.93 by $2.63. The firm had revenue of $3.55 billion during the quarter, compared to the consensus estimate of $3.38 billion. Regeneron Pharmaceuticals had a return on equity of 16.80% and a net margin of 32.04%. The firm’s revenue was up 12.3% on a year-over-year basis. During the same period in the prior year, the business earned $8.79 EPS. As a group, analysts anticipate that Regeneron Pharmaceuticals will post 37.8 EPS for the current year.

Insider Activity at Regeneron Pharmaceuticals

In other Regeneron Pharmaceuticals news, CFO Christopher R. Fenimore sold 5,680 shares of the company’s stock in a transaction dated Wednesday, August 28th. The shares were sold at an average price of $1,205.33, for a total transaction of $6,846,274.40. Following the completion of the sale, the chief financial officer now directly owns 15,305 shares of the company’s stock, valued at $18,447,575.65. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. In related news, EVP Joseph J. Larosa sold 1,866 shares of the company’s stock in a transaction on Thursday, July 11th. The stock was sold at an average price of $1,088.95, for a total transaction of $2,031,980.70. Following the transaction, the executive vice president now directly owns 37,937 shares of the company’s stock, valued at $41,311,496.15. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, CFO Christopher R. Fenimore sold 5,680 shares of the firm’s stock in a transaction dated Wednesday, August 28th. The stock was sold at an average price of $1,205.33, for a total value of $6,846,274.40. Following the sale, the chief financial officer now owns 15,305 shares of the company’s stock, valued at $18,447,575.65. The disclosure for this sale can be found here. Insiders sold 9,270 shares of company stock worth $10,695,833 in the last quarter. 7.48% of the stock is owned by company insiders.

Institutional Trading of Regeneron Pharmaceuticals

A number of hedge funds have recently made changes to their positions in REGN. Gilbert & Cook Inc. lifted its position in Regeneron Pharmaceuticals by 8.3% in the 4th quarter. Gilbert & Cook Inc. now owns 1,907 shares of the biopharmaceutical company’s stock worth $1,675,000 after buying an additional 146 shares in the last quarter. TrinityPoint Wealth LLC raised its holdings in shares of Regeneron Pharmaceuticals by 4.8% during the fourth quarter. TrinityPoint Wealth LLC now owns 262 shares of the biopharmaceutical company’s stock worth $230,000 after acquiring an additional 12 shares in the last quarter. D.A. Davidson & CO. boosted its position in Regeneron Pharmaceuticals by 17.0% during the fourth quarter. D.A. Davidson & CO. now owns 709 shares of the biopharmaceutical company’s stock valued at $623,000 after purchasing an additional 103 shares during the last quarter. US Bancorp DE grew its stake in Regeneron Pharmaceuticals by 6.7% in the fourth quarter. US Bancorp DE now owns 4,941 shares of the biopharmaceutical company’s stock valued at $4,340,000 after purchasing an additional 310 shares in the last quarter. Finally, Congress Wealth Management LLC DE acquired a new position in Regeneron Pharmaceuticals in the 4th quarter worth about $271,000. 83.31% of the stock is owned by hedge funds and other institutional investors.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.